<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301600</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0606</org_study_id>
    <nct_id>NCT00301600</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy</brief_title>
  <official_title>Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center random parallel study to compare the efficacy and safety of Mycophenolate&#xD;
      mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA&#xD;
      nephropathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IgA nephropathy is an immune-complex glomerulopathy that can result in capillary necrosis or&#xD;
      extracapillary proliferation (crescents). Several studies have documented a higher incidence&#xD;
      of hypertension and nephritic-range proteinuria in patients with the crescentic form of IgA&#xD;
      nephropathy, suggesting that patients with this variant of the disease may have a worse&#xD;
      prognosis. Some studies have shown that treatment with steroids and cyclophosphamide had&#xD;
      efficacy on reducing proteinuria and preserving renal function by healing vasculitic lesions,&#xD;
      therefore preventing the progression of glomerular sclerosis. Recent studies have also shown&#xD;
      that mycophenolate mofetil is effective in the treatment of lupus nephritis with vasculitic&#xD;
      lesion and small vasculitis with renal involvement. We will conduct a single-center&#xD;
      prospective open-labeled clinical trial of 40 patients with crescentic IgA nephropathy and&#xD;
      treat them randomly with pulse intravenous cyclophosphamide or oral mycophenolate mofetil.&#xD;
      After 12 months of treatment, we will assess the efficacy, safety, tolerability and relapse&#xD;
      of mycophenolate mofetil compared with cyclophosphamide in the treatment of crescentic IgA&#xD;
      nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofeti</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>MMF,1.0g/d</description>
    <arm_group_label>Mycophenolate mofeti</arm_group_label>
    <other_name>MMF,cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient with a diagnosis of IgAN without deposition of C4 and C1q, age 10-70y, sex free&#xD;
&#xD;
          1. Gross hematuria or an active urine sediment&#xD;
&#xD;
          2. Segmental necrotizing lesion of the capillary wall&#xD;
&#xD;
          3. Cellular or fibrocellular crescents ≥ 10%&#xD;
&#xD;
          4. Fibrinoid degeneration of small vessels&#xD;
&#xD;
          5. Fibrin positive Three or more items, with provision of criteria informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than four-week treatment with cytotoxic drug, such as CTX, CsA and MMF, prior to&#xD;
             enrollment&#xD;
&#xD;
          2. Immune deficiency&#xD;
&#xD;
          3. Serum creatinine ≥ 5.0mg/dl&#xD;
&#xD;
          4. Previous malignancy&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Hepatitis&#xD;
&#xD;
          7. Diabetic mellitus or obesity&#xD;
&#xD;
          8. Severe infection or CVS complications&#xD;
&#xD;
          9. Henoch-Schonlein purpura nephritis, systemic vasculitis, SLE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei-Shi Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Nanjing University School of Medicine</organization>
  </responsible_party>
  <keyword>Crescentic IgA nephropathy</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

